Abstract #3371
Diffusion and perfusion MRI for prediction of HCC response to neoadjuvant immunotherapy
Enamul Bhuiyan1,2, Paul Kennedy1,2, Octavia Bane1,2, Muhammed Shareef2, Stefanie Hectors3, Hung Kam Cheung 3, Elizabeth Miller3, M. Isabel Fiel4, Myron Schwartz5, Stephen Ward4, Thomas Marron6, Miriam Merad7, and Bachir Taouli1,2
1BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3Regeneron Pharmaceuticals Inc. Tarrytown, New York, NY, United States, 4Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 5Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 6The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 7Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Synopsis
Neoadjuvant immunotherapy has the potential to decrease the risk of hepatocellular carcinoma (HCC) recurrence post resection. The objectives of this study were to assess the value of pre-treatment MRI parameters for prediction of HCC immunophenotype and response in a cohort of patients undergoing neoadjuvant immunotherapy prior to liver resection. We hypothesize that diffusion and perfusion MRI can predict HCC response to neoadjuvant immunotherapy. It was observed that abundant of TILs decreases ADC in tumors. Moreover, uptake rate is higher in highly necrotic tumors.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
